You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》招銀國際下調康方生物(09926.HK)目標價至51.23元 評級「買入」
阿思達克 09-06 11:21
招銀國際發表研報指,康方生物(09926.HK)中期收入達到36.8億元人民幣,其中約7.95億元人民幣來自核心產品AK104及AK105的銷售,而約29.2億元人民幣則來自於AK112相關許可收入,當中AK104過去十二個月銷售額已達11.5億元人民幣,超過公司上市後首年10億元人民幣的目標。 該行指出,康方生物上半年產品毛利率達90.3%,與去年下半年約91.5%相若,而整體銷售費用佔產品銷售額的百分比則從2022年下半年的66.9%,降至今年上半年的60.3%。 撇除許可收入和股權投資虧損後,公司中期經營淨虧損收窄至2.56億元人民幣,招銀國際指出,預期AK104和AK112擁有龐大發展潛力,又指公司在非腫瘤業務發展良好,部分項目已接近商業化階段,PCSK9及IL12/23的新藥上市申請正在審核當中,維持「買入」評級,基於估值模型將目標價從52.65元下調至51.23元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account